« Back to Record
Goldhirsch, A., Gelber, R., Piccart-Gebhart, M., de Azambuja, E., Dal Lago, L., Procter, M., McFadden, E., Suter, T., Jackisch, C., Cameron, D. A., Weber, H. H., Heinzmann, D., Dowsett, M., Untch, M., Gianni, L., Bell, R. H., Köhne, C. H., Vindevoghel, A., Andersson, M., Brunt, A. M., Otero-Reyes, D., Song, S., Smith, I., Leyland-Jones, B., & Baselga, J. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial. Lancet, 382(9897), 1021-1028. doi:10.1016/S0140-6736(13)61094-6
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/183184



